Involvement of Altered B7 Expression in Dioxin Immunotoxicity: B7 Transfection Restores the CTL but Not the Alloantibody Response to the P815 Mastocytoma

Journal of Immunology

Volumn 158, Issue 6, 1997, Pages 2695-2703

  Prell, Rodney A ^a   Kerkvliet, Nancy I ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ALLOANTIBODY; B7 ANTIGEN; CD11B ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; MEMBRANE PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; C3H MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DBA MOUSE; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOUSE; SARCOMA; SPLEEN;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, CD80; ANTIGENS, CD86; ANTILYMPHOCYTE SERUM; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; ISOANTIBODIES; MACROPHAGE-1 ANTIGEN; MALE; MAST-CELL SARCOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TETRACHLORODIBENZODIOXIN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031569108     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Allison, J. P. 1994. CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol. 6:414.
2. Boussiotis, V. A., J. G. Gribben, G. J. Freeman, and L. M. Nadler. 1994. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr. Opin. Immunol. 6:797.
3. Chen, L., P. S. Linsley, and K. E. Hellström. 1993. Costimulation of T cells for tumor immunity, Immunol. Today 14:483.
4. Harlan, D. M., R. Abe, K. P. Lee, and C. H. June. 1995. Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. Clin. Immunol. Immunopathol. 75:99.
5. Guerder, S., S. R. Carding, and R. A. Flavell. 1995. B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. J. Immunol. 155:5167.
6. Guinan, E. C., J. G. Gribben, V. A. Boussiotis, G. J. Freeman, and L. M. Nadler. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261.
7. Johnson, S. G., and M. K. Jenkins. 1992. Co-stimulatory functions of antigen-presenting cells. J. Invest. Dermatol. 99:62S.
8. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065.
9. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L.-J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
10. Freedman, A. S., G. J. Freeman, K. Rhynhart, and L. M. Nadler. 1991. Selective induction of B7/BB1 on interferon-γ stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell. Immunol. 137:429.
11. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
12. Hathcock, K. S., G. Laszlo, H. B. Dickler, J. Bradshaw, P. Linsley, and R. J. Hodes. 1993. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262:905.
13. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, K. S. Hathcock, G. Laszlo, A. J. McKnight, J. Kim, L. Du, D. B. Lombard, G. S. Gray, L. M. Nadler, and A. H. Sharpe. 1993. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907.
14. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, Jr., L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
15. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. Hathcock, G. Laszlo, L. A. Lombard, S. Wang, G. S. Gray, L. M. Nadler, and A. H. Sharpe. 1993, Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178:2185.
16. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P. S. Linsley, S. Ikehara, S. Muramatsu, R. J. Hodes, and R. M. Steinman. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180:1849.
17. Engel, P., J. G. Gribben, G. J. Freeman, L.-J. Zhou, Y. Nozawa, M. Abe, L. M. Nadler, H. Wakasa, and T. F. Tedder. 1994. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood 84:1402.
18. Mondino, A., and M. K. Jenkins. 1994. Surface proteins involved in T cell costimulation. J. Leukocyte Biol. 55:805.
19. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
20. Lenschow, D. J., A. I. Sperling, M. P. Cooke, G. Freeman, L. Rhee, D. C. Decker, G. Gray, L. M. Nadler, C. C. Goodnow, and J. A. Bluestone. 1994. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153:1990.
21. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
22. Lindsten, T., C. H. June, J. A. Ledbetter, G. Stella, and C. B. Thompson. 1989. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339.
23. Walter, H., S. Schepensn, J. V. Wauwe, and M. de Boer. 1994. Ligation of CD28 by resting T cells by its ligand results in the induction of both Th1 - and Th2-type cytokines. Eur. Cytokine Netw. 5:13.
24. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
25. Guerder, S., J. Meyerhoff, and R. Flavell. 1994. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1:155.
26. Chen, C., and N. Nabavi. 1994. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1:147.
27. Van Parijs, L., A. Ibraghimov, and A. K. Abbas. 1996. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 4:321.
28. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
29. Bluestone, J. A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555.
30. Poland, A., and J. C. Knutson. 1982. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu. Rev: Pharmacol. Toxicol. 22:517.
31. Landers, J. P., and N. J. Bunce. 1991. The Ah receptor and the mechanism of dioxin toxicity. Biochem. J. 276:273.
32. Whitlock, J. P. Jr. 1993. Mechanistic aspects of dioxin action. Chem. Res. Toxicol. 6:754.
33. Nebert, D. W., A. Puga, and V. Vaciliou. 1993. Role of the Ah recepior and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann. NY Acad. Sci. 685:624.
34. Greenlee, W. F., K. M. Dold, R. D. Irons, and R. Osborne. 1985. Evidence for direct action of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on thymic epithelium. Toxicol. Appl. Pharmacol. 79:112.
35. Abbott, B. D., M. W. Harris, and L. S. Birnbaum. 1992. Comparisons of the effects of TCDD and hydrocortisone on growth factor expression provide insight into the synergistic interactions occurring in embryonic palates. Teratology 45:35.
36. Gaido, K. W., and S. C. Maness. 1994. Regulation of gene expression and acceleration of differentiation in human keratinocytes by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 127:199.
37. Kerkvliet, N. I., and G. R. Burleson. 1994. Immunotoxicity of TCDD and related halogenated aromatic hydrocarbons. In Immunotoxicology and Immunopharmacology, 2nd Ed. J. H. Dean, M. I. Luster, A. E. Munson, and I. Kimber, eds. Raven Press, NY, p. 97.
38. Kerkvliet, N. I. 1994. Immunotoxicology of dioxins and related chemicals. In Dioxins and Health. A. Schecter, ed. Plenum Press, New York, p. 199.
39. Kerkvliet, N. I., and L. Baecher-Steppan. 1988. Suppression of allograft immunity by 3,4,5,3′,4′,5′-hexachlorobiphenyl. I. Effects of exposure on tumor rejection and cytotoxic T cell activity in vivo. Immunopharmacology 16:1.
40. DeKrey, G. K., and N. I. Kerkvliet. 1995. Suppression of cytotoxic T lymphocyte activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin occurs in vivo, but not in vitro, and is independent of corticosterone elevation. Toxicology 97:105.
41. Kerkvliet, N. I., L. Baecher-Steppan, B. B. Smith, J. A. Youngberg, M. C. Henderson, and D. R. Buhler. 1990. Role of the Ah locus in suppression of cytotoxic T lymphocyte activity by halogenated aromatic hydrocarbons (PCBs and TCDD): structure-activity relationships and effects in C57BL/6 mice congenic at the Ah locus. Fundam. Appl. Toxicol. 14:532.
42. Clark, D. A., G. Sweeney, S. Safe, E. Hancock, D. G. Kilburn, and J. Gauldie. 1983. Cellular and genetic basis for suppression of cytotoxic T cell generation by haloaromatic hydrocarbons. Immunopharmacology 6:143.
43. Kerkvliet, N. I., L. Baecher-Steppan, D. M. Shepherd, J. A. Oughton, B. A. Vorderstrasse, and G. K. DeKrey. 1996. Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Immunol. 157:2310.
44. MEL-14(LECAM-1), Pgp-1, LFA-1, and VLA-4α during the differentiation of cytotoxic T lymphocytes induced by allografts. J. Immunol. 148:2348.
45. DeKrey, G. K., L. Baecher-Steppan, J. A. Deyo, B. Smith, N. I. Kerkvliet. 1993. PCB-induced immune suppression: castration, but not adrenalectomy or RU 38486 treatment, partially restores the cytotoxic T lymphocyte response to alloantigen. J. Pharmacol. Exp. Ther. 267:308.
46. Devens, B. H., and D. R. Webb. 1995. Phenotypic identification of specific and nonspecific suppressor T-cell populations involved in the in vivo response to alloantigen. Cell. Immunol. 161:1.
47. Yang, G., K. E. Hellström, I. Hellström, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
48. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1791.
49. Gajewski, T. F., J.-C. Renauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154:5637.
50. + T cells by B7-transfected melanoma cells. Science 259:368.
51. Chen, L., S. Ashe, W. A. Brady, I. Hellström, K. E. Hellström, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of amitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
52. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X.-Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 5:523.
53. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Tb2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
54. Lenschow, D. J., Y. Zeng, K. S. Hathcock, L. A. Zuckerman, G. Freeman, J. R. Thistlethwaite, G. S. Gray, R. J. Hodes, and J. A. Bluestone. 1995. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 60:1171.
55. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
56. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793.
57. Natesan, M., Z. Razi-Wolf, and H. Reiser. 1996. Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. J. Immunol. 156:2783.
58. Miller, S. D., C. L. Vanderlugt, D. J. Lenschow, J. G. Pope, N. J. Karandikar, M. C. Dal Canto, and J. A. Bluestone. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapse of murine EAE. Immunity 3:739.
59. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host of expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
60. Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Phillips, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:97.
61. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792.
62. Damle, N. K., P. S. Linsley, and J. A. Ledbetter. 1991. Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7. Eur. J. Immunol. 21:1277.
63. Watson, G. A., and D. M. Lopez. 1995. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J. Immunol. 155:3124.
64. Moser, M., T. De Smeldt, T. Sornasse, F. Tielemans, A. A. Chentoufi, E. Muraille, M. Van Mechelen, J. Urbain, and O. Leo. 1995. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur. J. Immunol. 25: 2818.